Case studies
Asset valuation – Due diligence
An agile and efficient methodology to value drug discovery pipelines in due diligence processes.
Challenge
A pharmaceutical group needed to value the pipeline of one of its companies for a due diligence process related to a divestment.
The group needed an external valuation to provide an objective basis for further negotiations with third parties and to decide which assets to keep within its parent structure.
Solution
We studied each project in the company’s pipeline in various therapeutic areas and at different stages of development, both pre-clinical and clinical.
We weigh the valuation based on intellectual protection, market interest, competitive status, stage of development of each project, likelihood of success and time to market.
We consider information related to industry deals for benchmarking and develop a business case for each product in the pipeline.
We analyse internal resources and look for the best partners to co-develop the right technologies and reduce time to market.
Result
- Robust valuation of the individual projects and the company’s pipeline in general.
- The pharmaceutical group was able to conduct further negotiations and due diligence processes based on the report and the valuation determined therein, as well as to decide which assets should be kept within the parent company.
“We developed a business case for each product in the pipeline.
Success case studies in the sector Biotech
Case studies of Business Plan